Please login to the form below

Not currently logged in
Email:
Password:

neutropaenia

This page shows the latest neutropaenia news and features for those working in and with pharma, biotech and healthcare.

Neulasta rival from Teva cleared in EU

Neulasta rival from Teva cleared in EU

Lonquex offers competition to Amgen drug in neutropaenia. Teva Pharmaceutical has been given a green light by the European Commission (EC) for Lonquex, a rival to Amgen's blockbuster Neulasta. ... Lonquex (lipegfilgrastim) has been approved to reduce the

Latest news

  • Lonza ends biosimilars deal with Teva Lonza ends biosimilars deal with Teva

    Teva's current efforts in the area include tbo-filgrastim - a biosimilar version of Amgen's Neupogen, which is approved for use  to hasten recovery from instances of neutropaenia in certain

  • R&D news in brief

    ìThe drug appears to be well tolerated, with thrombocytopaenia and neutropaenia, being the main side effects that require careful monitoring.î.

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

How does the government plan to reshape the NHS?
Oli Hudson, of Wilmington Healthcare, explores the government’s new white paper, which proposes key reforms for health and social care...
Want to give perfect client service? Tough luck, you’re human
In this article an ex-client of mine, Liz Skrbkova, and I explore the (unhelpful) pressures of trying to perfect the client-agency relationship...
WHITE PAPER: Why do men die younger?
It’s a commonly accepted fact that women outlive men. Wherever you live, there’s a good chance that men will die on average eight years earlier than women. Is this an...

Infographics